Comparative Pharmacology
Head-to-head clinical analysis: GIVLAARI versus OXLUMO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GIVLAARI versus OXLUMO.
GIVLAARI vs OXLUMO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GIVLAARI (givosiran) is an aminolevulinate synthase 1 (ALAS1)-directed small interfering RNA (siRNA) that reduces ALAS1 mRNA expression in hepatocytes, thereby decreasing circulating aminolevulinic acid (ALA) and porphobilinogen (PBG) levels.
Lumasiran is a small interfering RNA (siRNA) that targets the mRNA encoding hydroxyacid oxidase 1 (HAO1), leading to degradation of HAO1 mRNA and reduced synthesis of glycolate oxidase (GO). This decreases the production of glyoxylate, a substrate for oxalate synthesis, thereby lowering hepatic oxalate production and urinary oxalate excretion.
2.5 mg/kg intravenously over 15 minutes once every 4 weeks.
1 mg/kg subcutaneously once weekly
None Documented
None Documented
The terminal elimination half-life (t1/2) is approximately 6 days (range 4–8 days) in patients with acute hepatic porphyria. This long half-life supports monthly subcutaneous dosing.
Terminal elimination half-life is approximately 3–5 hours in adults with normal renal function; prolonged to 12–24 hours in moderate to severe renal impairment (CrCl <30 mL/min). Clinical context: dosing interval adjustment is required for renal impairment.
Givlaari (givosiran) is eliminated primarily via the liver, with minimal renal excretion. Approximately 30% of the dose is excreted in feces unchanged, and less than 10% is excreted in urine. The remainder is metabolized hepatically.
Primarily renal: ~70% of dose excreted unchanged in urine; ~30% metabolized via oxidation (likely CYP3A4) and excreted as metabolites in urine (20%) and feces (10%).
Category C
Category C
RNAi Therapeutic
RNAi Therapeutic